After Modi biopic, Vivek Oberoi gearing up to contest from Gujarat in 2024 polls

Mumbai, Jun 19: The Mumbai Police, probing the   case of alleged suicide of Bollywood actor Sushant Singh Rajput, has sent a letter to Yash Raj Films, seeking details of the contracts it had signed with him, an official said on Friday.

Rajput, 34, known for films like Kai Po Che!, MS Dhoni: The Untold Story, Chhichhore, was found hanging in his Bandra apartment on Sunday, sending shockwaves in the film industry and elsewhere.

"Police are investigating various angles, including that of professional rivalry, in the case," the official said. So far, Bandra police have recorded the statements of over 13 people, including Rajput's family members and close friends like actor Rhea Chakraborty and casting director Mukesh Chhabra.

 "Keeping in view the professional angle, police have started calling some prominent production houses for inquiry. As part of that, police on Thursday sent a letter to Yash Raj Films, seeking details of all the contracts it had signed with the deceased actor," a senior police officer said.

"We have also asked for the copies of the contracts that Yash Raj Films had signed with the actor," he added.

In the next few days, police may also call those people, who had played a role in signing of contracts between the actor and the production houses for their projects, the officer said.

 Rajput had worked in two Yash Raj Films movies - Shuddh Desi Romance (2013) directed by Maneesh Sharma and in director Dibakar Banerjee directed Detective Byomkesh Bakshy! (2015).

His third film with the banner was supposed to be Paani, directed by Shekhar Kapur. However, YRF had reportedly backed out of the project later.

Bhopal, Mar 4: Madhya Pradesh Chief Minister  Kamal Nath on Tuesday asserted that there was no threat to his government.

Nath's comments came when he was asked about reports of alleged 'poaching' attempts being made by the opposition BJP in the state.

“The legislators are telling me that they are being offered so much money. I am telling the MLAs to take it, if they are getting this free money,” Nath told reporters here on the sidelines of a programme.

Congress veteran Digvijaya Singh on Monday alleged that his party MLAs were being offered “huge money by BJP leaders” as part of the saffron party's “poaching” attempt to destablise the Kamal Nath government.

When Nath was asked about any threat to the stability of his government in Madhya Pradesh, he said, “There is nothing to worry about.”

Reacting to Nath's statement, state BJP spokesman Rajneesh Agrawal told PTI that his party has nothing to do with the allegations.

“In fact, these speculations and allegations are part of the internal bickering of among Congress leaders to get nominated for the Rajya Sabha polls,” he said.

After Digvijaya Singh's remarks on Monday, senior BJP leader and former chief minister Shivraj Singh Chouhan accused the Congress veteran of making false statements to create sensationalism.

“Speaking lies to create sensationalism is Digvijaya's habit. Probably some of his (Digivijaya's) works were not done and he wants to create pressure on the CM to get them done,” Chouhan alleged.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.